Literature DB >> 11809245

No reduction in cardiovascular risk with NSAIDs-including aspirin?

John G F Cleland1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809245     DOI: 10.1016/S0140-6736(02)07332-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Article makes simple errors and could cause unnecessary deaths.

Authors:  Colin Baigent; Rory Collins; Richard Peto
Journal:  BMJ       Date:  2002-01-19

2.  Chronic aspirin is effective--if data are massaged sufficiently.

Authors:  John G F Cleland
Journal:  BMJ       Date:  2002-02-02

3.  What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).

Authors:  Eric Wooltorton
Journal:  CMAJ       Date:  2002-06-25       Impact factor: 8.262

Review 4.  Aspirin for the prevention of cardiovascular events in the elderly.

Authors:  Isabelle Mahé; Alain Leizorovicz; Charles Caulin; Jean-François Bergmann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis.

Authors:  Helmut Schmidt; Barry G Woodcock; Gerd Geisslinger
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.